Robert Driscoll
Stock Analyst at Wedbush
(2.91)
# 1,629
Out of 5,090 analysts
153
Total ratings
38.52%
Success rate
0.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $11.95 | +217.99% | 11 | Nov 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $80 | $79.64 | +0.45% | 8 | Nov 6, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $31 → $38 | $10.24 | +271.09% | 2 | Oct 20, 2025 | |
| REPL Replimune Group | Upgrades: Outperform | $4 → $18 | $10.61 | +69.65% | 7 | Oct 20, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $13.07 | +106.58% | 1 | Jul 14, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.39 | +187.77% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $0.95 | +530.45% | 3 | May 9, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $17.41 | -2.35% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $12.79 | -6.18% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $7.92 | +304.04% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $35.87 | +44.97% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $21.50 | +30.23% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.67 | +499.25% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $25.45 | +17.88% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.53 | +835.98% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $10.59 | +239.94% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.06 | +937.74% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.36 | +198.17% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $9.63 | +34.99% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $16.51 | +348.21% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.53 | +44.67% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.31 | +434.35% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $3.95 | +102.53% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.42 | -9.50% | 4 | May 19, 2020 |
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $11.95
Upside: +217.99%
Revolution Medicines
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $79.64
Upside: +0.45%
Corbus Pharmaceuticals Holdings
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $10.24
Upside: +271.09%
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $4 → $18
Current: $10.61
Upside: +69.65%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $13.07
Upside: +106.58%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.39
Upside: +187.77%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.95
Upside: +530.45%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $17.41
Upside: -2.35%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $12.79
Upside: -6.18%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $7.92
Upside: +304.04%
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $35.87
Upside: +44.97%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $21.50
Upside: +30.23%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.67
Upside: +499.25%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $25.45
Upside: +17.88%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.53
Upside: +835.98%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $10.59
Upside: +239.94%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.06
Upside: +937.74%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.36
Upside: +198.17%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $9.63
Upside: +34.99%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $16.51
Upside: +348.21%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.53
Upside: +44.67%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.31
Upside: +434.35%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $3.95
Upside: +102.53%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.42
Upside: -9.50%